Treatment of renal congestion by tolvaptan
Treatment of renal congestion by tolvaptan
复制标题
托伐普坦治疗肾充血
DOI:
10.1038/s41440-019-0215-9
复制
发表时间:
2019
影响因子:
5.4
通讯作者:
Kinugasa Satoshi
中科院分区:
文献类型:
--
作者:
Mori Takefumi;Hirose Takuo;Kinugasa Satoshi
Reduced renal function is associated with increased cardiovascular events and mortality, and chronic kidney disease is a risk factor for heart failure. Conversely, heart failure is a known risk factor for renal dysfunction. Thus, a vicious cycle is formed, mediated by cardio-renal functional correlations, and this cycle is commonly observed in patients with heart failure and exacerbates the prognosis of the disease [1].Several mechanisms have been reported to be involved in the cardio-renal connection. Notably, vasoconstrictive neurohormones including the renin–angiotensin system, vasopressin and catecholamines are known to play a major role. In heart failure, arterial underfilling stimulates these neurohormones, which induce renal ischemia, hypoxia, and Na retention and enhance volume overload. In this regard, a recent report by Chiba et al.[2] examined the mechanism of the cardio-renal connection using Dahl salt-sensitive rats and a model of hypertensive cardiorenal failure. They conducted a study in which renal hemodynamic changes were measured during the induction of heart failure. Local renal blood flow (RBF) was measured by renal ultrasound, and renal medullary pressure was measured using a fiber-optic pressure sensor. The resistance index and venous impedance index were significantly increased in response to hypertensive cardio-renal failure by a high salt diet, suggesting that renal medullary blood flow was reduced.